Dr. Yuk- Ching Tse-Dinh's research paper entitled "Small Molecule Inhibitors Targeting Topoisomerase I as Novel Antituberculosis Agents" was accepted for early online posting by the journal of Antimicrobial Agents and Chemotherapy. This work results from a 3-way collaboration between Dr. Tse-Dinh's research group here at FIU, the group led by Dr. Richard Houghten, President of Torrey Pines Institute for Molecular Studies, and the research group led by Kyle Rohde, Assistant Professor, Infectious Disease, Burnett School of Biomedical Sciences, University of Central Florida College of Medicine.
The research focus on Tuberculosis (TB); it affects 9.6 million people a year and causes 1.5 million deaths each year. The problem presented by multidrug resistance is illustrated by the 480,000 cases of multidrug-resistant TB (MDR-TB) that do not respond to ﬁrst-line treatment drugs, with around 10% of these cases being extensively drug-resistant tuberculosis (XDR-TB) cases that are resistant to even some of the second-line drugs. New combinations of anti-TB drugs are needed to treat the MDR-TB and XDR-TB cases. This new publication describes how novel compounds that provide useful starting points for further optimization and development into a new TB drug candidate.
FIU graduate students Shayna Sandhaus (first author), Pamela Garcia and undergraduate student Angelo Andres are coauthors on this publication and are part of the Tse-Dinh research lab.
Congratulations to all!